IMRX
$5.06
$-0.04 (-0.77%)-0.77%
ClosedLoading chart...
IndexN/A
Market Cap0.18B
Enterprise Value0.16B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-4.87
P/S0.00
P/B1.33
P/C-6.37
EV/EBITDA-2.98
EV/SalesN/A
EPS (ttm)-1.04
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.52M
Shs Outstand0.04B
Change-2.69%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $316.95K | $2.08M | $2.31M | $1.92M |
| Cost of Revenue | $0.00 | $0.00 | $158.12K | $1.15M | $1.28M | $1.22M |
| Gross Profit | $0.00 | $0.00 | $158.83K | $926.89K | $1.03M | $696.74K |
| Gross Margin | N/A | N/A | 50.11% | 44.56% | 44.61% | 36.29% |
| Operating Expenses | $64.07M | $58.41M | $51.90M | $34.81M | $18.11M | $6.99M |
| Operating Income | $-64.07M | $-58.41M | $-51.74M | $-33.89M | $-17.08M | $-6.29M |
| Operating Margin | N/A | N/A | -16325.77% | -1629.17% | -739.01% | -327.71% |
| Net Income | $-61.04M | $-53.47M | $-50.51M | $-33.54M | $-17.04M | $-7.71M |
| Net Margin | N/A | N/A | -15937.29% | -1612.33% | -737.17% | -401.59% |
| EPS (Basic) | $-2.04 | $-1.88 | $-1.87 | $-1.27 | $-1.26 | $-0.60 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $52.71M | $102.58M | $122.37M | $166.70M | $38.42M | $14.10M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $11.33M | $12.01M | $12.52M | $10.72M | $60.90M | $20.63M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $41.39M | $90.58M | $109.85M | $155.98M | $-22.48M | $-6.53M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $41.39M | $90.58M | $109.85M | $155.98M | $-22.48M | $-6.53M |
| Total Liabilities & Stockholders Equity | $52.71M | $102.58M | $122.37M | $166.70M | $38.42M | $14.10M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-61.04M | $-53.47M | $-50.51M | $-33.54M | $-17.04M | $-7.71M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-55.00M | $-48.97M | $-44.10M | $-30.85M | $-14.62M | $-4.44M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)Benzinga Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewswire Inc. Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025Benzinga Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving PremarketBenzinga Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to SanofiGlobeNewswire Inc. Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25GlobeNewswire Inc. Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer PatientsGlobeNewswire Inc. Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025GlobeNewswire Inc.
Show 12 more stories
Immuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc. Immuneering to Present at the Jefferies Global Healthcare ConferenceGlobeNewswire Inc. Immuneering Recognizes Melanoma Awareness MonthGlobeNewswire Inc. IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsGlobeNewswire Inc. Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc. Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsGlobeNewswire Inc. Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga Immuneering (IMRX) Plummets 71% in One Week: Here's WhyZacks Investment Research Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial DataBenzinga Dow Falls Over 200 Points; Adobe Shares PlungeBenzinga Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day SessionBenzinga Crude Oil Edges Lower; US Consumer Sentiment Falls In MarchBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Discover more
You may be interested in